Clovis Oncology (CLVS) Commences Enrollment of Lucitanib Phase 2 in FGFR1-Amplified NSCLC
Tweet Send to a Friend
Clovis Oncology (NASDAQ: CLVS) announced that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
